ZEOX Stock Overview
Zeo ScientifiX, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicines.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Zeo ScientifiX, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.50 |
| 52 Week High | US$4.80 |
| 52 Week Low | US$0.90 |
| Beta | 4.4 |
| 1 Month Change | -28.57% |
| 3 Month Change | 3.45% |
| 1 Year Change | -21.05% |
| 3 Year Change | -86.84% |
| 5 Year Change | -85.58% |
| Change since IPO | -75.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| ZEOX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.3% | -5.0% | -3.5% |
| 1Y | -21.1% | -1.7% | 20.2% |
Return vs Industry: ZEOX underperformed the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: ZEOX underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| ZEOX volatility | |
|---|---|
| ZEOX Average Weekly Movement | 28.9% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ZEOX's share price has been volatile over the past 3 months.
Volatility Over Time: ZEOX's weekly volatility has increased from 24% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 23 | Harry Leider | www.zeoscientifix.com |
Zeo ScientifiX, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicines. Its lead product candidate is Zofin, an acellular biologic therapeutic derived from perinatal sources, which is in Phase I/II clinical trial to treat COVID-19, chronic obstructive pulmonary disease, and knee osteoarthritis. The company also provides Patient Pure X, an autologous blood-derived biologic technology, that is placed in the body for exosomes the cascade of cellular reprogramming and tissue repair.
Zeo ScientifiX, Inc. Fundamentals Summary
| ZEOX fundamental statistics | |
|---|---|
| Market cap | US$9.80m |
| Earnings (TTM) | -US$5.74m |
| Revenue (TTM) | US$4.64m |
2.0x
P/S Ratio-1.6x
P/E RatioIs ZEOX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZEOX income statement (TTM) | |
|---|---|
| Revenue | US$4.64m |
| Cost of Revenue | US$562.63k |
| Gross Profit | US$4.08m |
| Other Expenses | US$9.82m |
| Earnings | -US$5.74m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.94 |
| Gross Margin | 87.88% |
| Net Profit Margin | -123.64% |
| Debt/Equity Ratio | -44.0% |
How did ZEOX perform over the long term?
See historical performance and comparison